Dynavox: Operating Leverage Flexes as Prescription Delays Cloud a Slowing Growth Engine

EBIT more than doubles on a 16% FX-adjusted quarter, but the new theme — longer US prescription timelines — is the real story investors must track into H2.

DYVOX.ST · Earnings Call · 2026-07-22

A quarter of contradictions

Dynavox Group's Q2 2026 is the rare report where profitability outshines the revenue line — with a symmetry that feeds both confidence and a nagging question. Revenue grew 16% currency-adjusted to SEK 670 million, a solid number that collides with last year's exceptional 38% comp and the company's own 20% target. Yet operating profit more than doubled: EBIT +137% to SEK 105 million (15.7% margin), basic EPS up roughly 159% to SEK 0.70, and cash flow after continuous investment up 167% to SEK 67 million. The operating leverage is real, and the prescription lead times — or rather their absence — are the reason the profit line printed so hard while top-line growth decelerated. But the fresh theme that dominates the Q&A is not the profit print. It is the stretching of the entire prescription timeline in the US, a word that had almost no presence in Dynavox's prior four quarters and now anchors the 20263 keyword set (alongside insurance provider, "new therapist," and "prescription processes"). This is a genuinely company-unique theme, not sector boilerplate.

The new theme: bureaucracy, not lost demand

For a business where ~90% of revenue flows through public or private insurance, the reimbursement machinery is everything. The driver CEO Fredrik Ruben cites: a larger-than-usual population changing insurance providers at the turn of the year, which in turn forces a change of therapist and restarts the assessment — before a prescription is even submitted.

I'm not saying that you start from scratch, but there is a little bit of a rework... It's not like the reimbursement is taking longer. It's the entire prescription timeline that we notably see is longer this year than before.
Fredrik Ruben, Chief Executive Officer · 2026-07-22

Management's reassurance is emphatic and consistent with how it handled the Q1 winter-weather drag — the deferral-not-loss framing. In April, the same CEO argued: “Our assumption is that none of the lost revenue, if you will, that didn't happen due to weather impact, et cetera, are actually lost. They will happen later on in the year.” — Fredrik Ruben, CEO · 2026-04-24 He also had to acknowledge the arithmetic of the 20% target — “If you start the quarter with 15%, that obviously means that there is -- there needs to be some sort of acceleration there.” — Fredrik Ruben, CEO · 2026-04-24 None of the analysts on the July call got a date for that catch-up. When asked whether the impact would annualize into Q2 2027, the answer was blunt: “Your guess is as good as mine here.” — Fredrik Ruben, Chief Executive Officer · 2026-07-22 The market is left holding a thesis that demand is unchanged but the conversion funnel is slower — precisely the kind of story that either resolves into a deferred-revenue rebound or quietly erodes.

The forward question: component costs and the new CFO

The other new and quantifiable item is the drag on gross margin from memory/component inflation, including Apple's iPad price increases — the iPad is a key hardware platform for Dynavox devices. Having printed a strong 70% gross margin in Q2 (helped by ~1pp of favorable FX), CFO Linda Tybring cautioned: “We are seeing increase both on other components and the iPad or Apple cost. We think from a rolling 12 perspective, it's slightly below one percentage point going forward that we might have impact on gross margin.” — Linda Tybring, Chief Financial Officer · 2026-07-22 That ~1pp headwind is a partial offset to the operating-leverage story; whether the roughly 700 individually negotiated payer contracts and the year-end Medicare allowable updates compensate will be a key H2 question — plus the fresh noise around the U.S. lawsuit against AbleNet, whose cost the CFO dismissed as “not substantial at all.” — Linda Tybring, Chief Financial Officer · 2026-07-22 Two strategic moves round out the quarter: the completed global rollout of the new ERP system (non-recurring costs down to SEK 6M from SEK 18M), which management frames as the scalability back-end; and the closing of the Italian reseller partner acquisition, SR Labs Healthcare, contributing 4% to growth — consistent with the company's "sprinkle on the cake" M&A framing. Jacob Thordenberg joins as CFO in September, inheriting both the margin-headwind question and the prescription-timeline puzzle.

Why it matters

Dynavox remains a compelling, under-penetrated-market compounder — 75% of revenue from the U.S., a reimbursement-funded moat, and a 16% FX-adjusted quarter in a year with a brutal 38% comp. But Q2 crystallizes two things investors must now track forward: whether the longer lead times resolve into a revenue catch-up (or not), and whether the ~1pp component-cost drag on gross margin is offset by price updates and scale. If the prescription delays are true deferrals, the current ~15% reported growth is a lag, not a level; if they persist, the 20% average target gets harder to defend quarter by quarter.